Results 11 to 20 of about 1,641 (202)

Magnetocardiography in the Evaluation of Sudden Cardiac Death Risk: A Systematic Review [PDF]

Annals of Noninvasive Electrocardiology
Sudden cardiac death (SCD) is responsible for 15%–20% of deaths globally/year, predominantly due to ventricular arrhythmias (VA) caused by vulnerable cardiac substrate.
Thomas Lachlan, Hejie He, Kengo Kusano, Takeshi Aiba, Donatella Brisinda, Riccardo Fenici, Faizel Osman   +6 more
doaj   +3 more sources

Benchmarking the clinical outcomes of Healthentia SaMD in chronic disease management: a systematic literature review comparison [PDF]

Frontiers in Public Health
BackgroundSoftware as a Medical Device (SaMD) and mobile health (mHealth) applications have revolutionized the healthcare landscape in the areas of remote patient monitoring (RPM) and digital therapeutics (DTx).
Sofoklis Kyriazakos, Aristodemos Pnevmatikakis, Konstantina Kostopoulou, Laurent Ferrière, Kyun Thibaut, Erika Giacobini, Roberta Pastorino, Roberta Pastorino, Marco Gorini, Peter Fenici   +9 more
doaj   +2 more sources

Patient perceptions of their glycemic control and its influence on type 2 diabetes outcomes: an international survey of online communities [PDF]

Patient Preference and Adherence, 2019
Kristina Simacek,1 Christopher Curran,1 Peter Fenici,2 Ricardo Garcia-Sanchez3 1PatientsLikeMe, Inc., Cambridge, MA, USA; 2AstraZeneca, Cambridge, UK; 3AstraZeneca, Gaithersburg, MD, USA Purpose: This study aimed to assess awareness of glycated ...
Simacek K, Curran C, Fenici P, Garcia-Sanchez R   +3 more
doaj   +2 more sources

A method for noninvasive beat-by-beat visualization of His bundle signals. [PDF]

Ann Noninvasive Electrocardiol, 2023
A novel method to unravel beat‐by‐beat surface recordings of His bundle signals is proposed. The method has been successfully demonstrated on 19 subjects for whom the invasive electrophysiological study had already been performed. This is inclusive of five subjects with BSPM measurements.
Sengottuvel S, Shenbaga Devi S, Sasikala M, Satheesh S, Selvaraj RJ.   +4 more
europepmc   +2 more sources

Letter to the Editor about the article: by C. Eskander, et al, “Magnetocardiography for noninvasive surveillance of rejection and cardiac allograft vasculopathy in heart transplant recipients,” Am. Hear. J. Plus Cardiol. Res. Pract., vol. 62, p. 100704,… [PDF]

American Heart Journal Plus
Donatella Brisinda, Peter Fenici, Riccardo Fenici   +2 more
doaj   +2 more sources

All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. [PDF]

Diabetes Obes Metab, 2023
Abstract Aims To understand geographical and temporal patterns in the diabetes gap, the excess mortality risk associated with type 2 diabetes (T2D), in three high‐income countries. Methods Using databases from Canada (Ontario), Spain (Catalonia) and the UK (England), we harmonized the study design and the analytical strategy to extract information on ...
Ling S, Zaccardi F, Vlacho B, Li P, Real Gatius J, Mata-Cases M, Franch-Nadal J, Kosiborod MN, Gillies C, Fenici P, Mauricio D, Shah BR, Khunti K.   +12 more
europepmc   +2 more sources

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme [PDF]

BMJ Open, 2020
Objectives To evaluate the extent to which patients with type 2 diabetes discontinue metformin therapy when initiating second-line treatment and factors associated with metformin discontinuation, using baseline data from the DISCOVER study programme ...
Peter Fenici, Niklas Hammar, Linong Ji, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Wolfgang Rathmann, Iichiro Shimomura, Marilia B Gomes, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Hungta Chen, Javier Cid-Ruzafa   +13 more
doaj   +2 more sources

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second-line glucose-lowering therapy: The global DISCOVER study. [PDF]

Diabetes Obes Metab, 2023
Abstract Aims To describe glucose‐lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow‐up from the start of second‐line therapy. Materials and Methods This data analysis from the 3‐year, observational DISCOVER study programme included 14 687 participants from 37 ...
Charbonnel BH, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes MB, Saraiva GL, Medina J, Nicolucci A, Shestakova MV, Shimomura I, Surmont F, Tang F, Vora J, Watada H, Khunti K, DISCOVER Investigators.   +16 more
europepmc   +2 more sources

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study [PDF]

BMJ Open Diabetes Research & Care, 2019
Objective To assess the eligibility of patients participating in DISCOVER (a 3-year, prospective, observational study program of 15 992 patients with type 2 diabetes [T2D] initiating a second-line glucose-lowering therapy across 38 countries) for four ...
Jesús Medina, Kamlesh Khunti, Stéphane Pintat, Peter Fenici, Niklas Hammar, Linong Ji, Fengming Tang, Eric Wittbrodt, Filip Surmont   +8 more
doaj   +2 more sources

Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. [PDF]

Diabetes Obes Metab, 2021
Abstract This study of real‐world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium‐glucose cotransporter‐2 (SGLT2) inhibitors versus other glucose‐lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF ...
Lam CSP, Karasik A, Melzer-Cohen C, Cavender MA, Kohsaka S, Norhammar A, Thuresson M, Chen H, Wittbrodt E, Fenici P, Kosiborod M, CVD-REAL Investigators and Study Group.   +11 more
europepmc   +2 more sources